Status:
COMPLETED
Myoglobin Removal With CytoSorb in Rhabdomyolysis
Lead Sponsor:
Sisli Hamidiye Etfal Training and Research Hospital
Conditions:
Acute Kidney Injury
Rhabdomyolysis
Eligibility:
All Genders
18-80 years
Brief Summary
The aim of this observational study is to assess whether myoglobin removal with CytoSorb® ameliorates endothelial damage in severe rhabdomyolysis patients who are admitted to the intensive care unit. ...
Detailed Description
Rhabdomyolysis is characterized by destruction of muscle by various causes and is diagnosed by increased creatine kinase concentrations in the blood. Myoglobin released into the blood may cause acute ...
Eligibility Criteria
Inclusion
- Patients with Creatine Kinase \> 5000 IU/L.
- Myoglobin results can be obtained only after 5 working days after sampling in our center, therefore it cannot be used as an inclusion criteria.
- GFR below 40 ml/min.
Exclusion
- High dose vasopressor requirement
- Not expected to survive \> 24 h
- Lack of consent to participate
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2025
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT06503289
Start Date
August 1 2024
End Date
May 1 2025
Last Update
June 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sisli etfal research and training hospital
Istanbul, Turkey (Türkiye), 34371